自身抗体阳性个体的1型糖尿病预测:性能、时间与成本均需考量
本研究基于TrialNet Pathway to Prevention研究中3967例自身抗体阳性1型糖尿病一级亲属数据,构建1943个Cox预测模型,比较包含代谢指标等不同变量的模型在预测性能、成本和受试者耗时上的差异,发现含代谢指标的模型性能最佳但成本与时间差异显著,成本-性能分析可识别权衡方案以定制风险筛查策略。
要点
- 含代谢指标的模型预测性能最佳,但多数模型间性能差异小于3%且p>0.05。
- 测量代谢变量的成本范围为56至293美元,受试者耗时范围为10至165分钟。
- OGTT衍生代谢指标模型与HbA1c或Index60衍生模型性能相似,但成本与时间差异重要。
核心结论
- 成本-性能模型分析识别了成本与性能模型之间的权衡,并确定了可定制风险筛查策略的成本最小化选项。
研究设计与样本
- 基于Cox模型构建1943个预测模型,使用TrialNet Pathway to Prevention研究中3967例自身抗体阳性1型糖尿病一级亲属的数据,训练集与验证集各半。
- 中位随访4.7年(IQR 2.0-8.1),1311例参与者发展为临床1型糖尿病。
主要发现
- 含代谢指标的模型预测性能最佳,多数模型间性能差异小于3%且p>0.05。
- 测量代谢变量的成本范围为56至293美元,受试者耗时范围为10至165分钟。
- 预测模型性能存在时间变异性,GRS2的影响力和判别力在最早临床前阶段最高。
- OGTT衍生代谢指标模型与HbA1c或Index60衍生模型性能相似,但成本与受试者时间差异重要。
关键数值与推荐
- 模型性能差异小于3%且p>0.05。
- 代谢变量测量成本56至293美元,受试者耗时10至165分钟。
临床怎么用
- 成本-性能模型分析可识别成本与性能之间的权衡,并确定成本最小化选项以定制风险筛查策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Efficient prediction of clinical type 1 diabetes is important for risk stratification and monitoring of autoantibody-positive individuals. In this study, we compared type 1 diabetes predictive models for predictive performance, cost and participant time needed for testing. METHODS: We developed 1943 predictive models using a Cox model based on a type 1 diabetes genetic risk score (GRS2), autoantibody count and types, BMI, age, self-reported gender and OGTT-derived glucose and C-peptide measures. We trained and validated the models using halves of a dataset comprising autoantibody-positive first-degree relatives of individuals with type 1 diabetes (n=3967, 49% female, 14.9 ± 12.1 years of age) from the TrialNet Pathway to Prevention study. The median duration of follow-up was 4.7 years (IQR 2.0-8.1), and 1311 participants developed clinical type 1 diabetes. Models were compared for predictive performances, estimated cost and participant time. RESULTS: Models that included metabolic measures had best performance, with most exhibiting small performance differences (less than 3% and p>0.05). However, the cost and participant time associated with measuring metabolic variables ranged between US$56 and US$293 and 10-165 min, respectively. The predictive model performance had temporal variability, with the highest GRS2 influence and discriminative power being exhibited in the earliest preclinical stages. OGTT-derived metabolic measures had a similar performance to HbA1c- or Index60-derived models, with an important difference in cost and participant time. CONCLUSIONS/INTERPRETATION: Cost-performance model analyses identified trade-offs between cost and performance models, and identified cost-minimising options to tailor risk-screening strategies.
引用
- Ferrat LA, Templeman EL, Steck AK, et al. Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter. Diabetologia. 2025. PMID: 40347237. doi:10.1007/s00125-025-06434-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。